Genetic polymorphism and Parkinson's disease in Taiwan: Study of debrisequine 4-hydroxylase (CYP2D6)

Journal of the Neurological Sciences

Volumn 158, Issue 1, 1998, Pages 38-42

  Lo, Hsiao Sui ^a   Chen, Chia Hsiang ^b   Hogan, Edward L ^c   Kao, Ko Pei ^d   Wang, Vinchi ^e   Yan, Sui Hing ^e  

^a TAIWAN ADVENTIST HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e CARDINAL TIEN HOSPITAL   (Taiwan)

Author keywords

Association; Chinese; CYP2D6; Genetics; Parkinson's disease

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE 4 HYDROXYLASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ANALYSIS; FEMALE; GENE FREQUENCY; GENE ISOLATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; DISEASE SUSCEPTIBILITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TAIWAN;

EID: 0032508057     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00094-X     Document Type: Article

References (43)

1. Agundez JAG, Martinez C, Ladero JMet al. Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther. 55:1994;10-14.
2. Agundez JAG, Jimemez-Jimenez FJ, Luengo Aet al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther. 57:1995;291-293.
3. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR Mutant debrisoquine hydroxylase genes in Parkinson's disease. Lancet. 339:1992;1017-1018.
4. Barbeau A, Pourcher E New data on the genetics of Parkinson's disease. Can J Neurol Sci. 9:1982;53-60.
5. Barbeau A, Cloutier T, Roy Met al. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet. 2:1985;1213-1216.
6. Benitez J, Ladero JM, Jimenez-Jimenez FJet al. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry. 53:1990;289-292.
7. Blin N, Stafford DW A general method for isolation of high molecular DNA from eukaryotes. Nucl Acids Res. 3:1976;2303-2308.
8. Bordet R, Broly F, Destee A, Libersa C Desbrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Adv Neurol. 69:1996;97-100.
9. Broly F, Marez D, Lo-uidice JMet al. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum Genet. 96:1995;601-603.
10. Chan P, Tanner CM, Langston JW A new CYP2D6 mutation associated with Parkinson's disease in American Caucasians. Movement Disord. 10:1995;689.
11. Comella CL, Tanner CM, Goetz CGet al. Debrisoquine metabolism in Parkinson's disease [abstract]. Neurology. 37(Suppl 1):1987;261-262.
12. Couper J On the effects of black oxide of manganese when inhaled into the lungs. Br Ann Med Pharm. 1:1837;41-42.
13. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjoqvist F Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther. 51:1992;12-17.
14. Daly AK, Leathart JBS, London SJ, Idle JR An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Hum Genet. 95:1995;337-341.
15. Douglas AM, Atchison BA, Somogyi AA, Drummer OH Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics. 4:1994;154-158.
16. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 17:1980;102-105.
17. Evans WE, Relling MV Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics. 1:1991;143-148.
18. Evert B, Griese EU, Eichelbaum M A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedebergs Arch Pharmacol. 350:1994;434-439.
19. Evert B, Griese EU, Eichelbaum M Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics. 4:1994;271-274.
20. Gasser T, Wszolek ZK, Trofatter Jet al. Genetic linkage studies in autosomal dominant Parkinsonism: evaluation of seven candidate genes. Ann Neurol. 36:1994;387-394.
21. Gasser T, Wszolek Z, Supala Aet al. Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Adv Neurol. 69:1996;87-95.
22. 1934→A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet. 47:1990;994-1001.
23. Hantraye P, Brouillet E, Ferrante Ret al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced Parkinsonism in baboons. Nature Med. 2:1996;1017-1021.
24. Heim M, Meyer UA Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet. 336:1990;529-532.
25. Ho SL, McCann KP, Bennett Pet al. The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Adv Neurol. 69:1996;53-60.
26. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem. 265:1990;17209-17214.
27. Kallio J, Marttila RJ, Rinne UKet al. Debrisoquine oxidation in Parkinson's disease. Acta Neurol Scand. 83:1991;194-197.
28. Kurth MC, Kurth JH Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet. 48:1993;166-168.
29. Langston JW, Ballard PA, Tetrud JW, Irwin I Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1984;979-980.
30. Liu TAU, Chi CW, Yang JC, Cheng SC, Liu HC Debrisoquine metabolism in Chinese patients with Alzheimer's and Parkinson's diseases. Mol Chem Neuropathol. 17:1992;31-37.
31. Llerena A, Heraiz AG, Cobaleda J, Johansson I, Dahl ML Debrisoquine and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther. 54:1993;606-611.
32. Lou YC, Ying L, Bertilsson L, Sjoqvist F Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. 2:1987;852-853.
33. Marez D, Sabbagh N, Legrand Met al. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics. 5:1995;305-311.
34. Ott J. Analysis of human genetic linkage, revised edition. Baltimore: Johns Hopkins University Press, 1991.
35. Plante-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry. 57:1994;911-913.
36. Sandy MS, Armstrong M, Tanner CMet al. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology. 47:1996;225-230.
37. Saxena R, Shaw GL, Relling MVet al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet. 3:1994;923-926.
38. Smith CAD, Gough AC, Leigh PNet al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 339:1992;1375-1377.
39. Steiger MJ, Lledo P, Quinn NPet al. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand. 86:1992;159-164.
40. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther. 44:1988;431-435.
41. Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y A novel cytochrome P-450IID6 mutant gene association with Parkinson's disease. J Biochem. 114:1993;263-266.
42. Wang SJ, Fuh JL, Liu CYet al. Parkinson's disease in Kin-Hu Kinmen: a community survey by neurologists. Neuroepidemiology. 13:1994;69-74.
43. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther. 53:1993;410-418.